Wednesday, October 4, 2023
Clinical Advances in
Antiplatelet therapy is a cornerstone in the cardiovascular disease (CVD) treatment continuum. However, challenges remain in clinical practice, including identifying patients at risk for CVD, selecting appropriate cardioprevention strategies with consideration for thrombotic and bleeding risk, and improving patient outcomes. This collection page will feature ongoing educational activities, tools, and expert insights to overcome common misconceptions and guide effective application of the latest guidelines and clinical data on cardioprevention across various patient populations.
Supported by an independent educational grant from
Bayer
Review the latest data on the role of aspirin in the primary prevention of cardiovascular events.
Download
Steering Committee Chair
Professor of Medicine
Harvard Medical School
Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Boston, Massachusetts
Professor of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University
Baltimore, Maryland
Professor of Medicine
Harvard Medical School
Education Director
Cardiovascular Innovation
Cardiovascular Division
Brigham and Women's Faulkner Hospital
Boston, Massachusetts
Professor of Medicine
Massachusetts General Hospital
Boston, Massachusetts
Professor of Medicine
Director of Interventional Cardiovascular Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, New York
Health Sciences Clinical Professor of Family Medicine
University of California, Irvine School of Medicine
Irvine, California
Steering Committee Chair
Has disclosed the following relevant financial relationships
Received grants for clinical research from: Abbott; Afimmune; Amarin; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cardax; Chiesi; CSL Behring; Eisai; Ethicon; Ferring Pharmaceuticals; Forest Laboratories; Fractyl; Idorsia; Ironwood; Ischemix; Lexicon; Lilly; Medtronic; Pfizer; PhaseBio; PLx Pharma; Regeneron; Roche; Sanofi Aventis; Synaptic; The Medicines Company
Participation by Dr Blaha does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen; Bayer; Novartis; Novo Nordisk; Regeneron; Sanofi
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Aegerion; Alynylam; Amarin; Amgen; Applied Therapeutics; Ascendia; Boehringer Ingelheim; Bristol-Myers Squibb; Corvidia; HLS Therapeutics; Innovent; Janssen; Kowa; Merck; Pfizer; Sanofi
Received grants for clinical research from: Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Merck; Pfizer
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bayer Pharma AG; Boehringer Ingelheim; Pfizer Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Abbott; AstraZeneca; Bayer; Boston Scientific Corporation; Bristol-Myers Squibb; CSL Behring; Daiichi Sankyo, Inc.; Janssen; Novartis; Sanofi
Served as a speaker or a member of a speakers bureau for: Abbott
Received grants for clinical research from: AstraZeneca; Bayer; Daiichi Sankyo, Inc.
Owns stock, stock options, or bonds from: Claret; Elixir
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: GlaxoSmithKline
Served as a speaker or a member of a speakers bureau for: Genentech